- $13.78m
- $12.15m
- $6.09m
- 90
- 78
- 53
- 86
Annual income statement for PharmChem, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2002 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | PRESS | PRESS |
Standards: | USG | USG | USG | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 30.1 | 6.22 | 5.84 | 6.01 | 6.09 |
Cost of Revenue | |||||
Gross Profit | 7.07 | 3.89 | 3.75 | 3.9 | 3.88 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 30.9 | 4.55 | 4.76 | 5.04 | 4.42 |
Operating Profit | -0.783 | 1.67 | 1.08 | 0.973 | 1.66 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.36 | 1.67 | 1.11 | 1.05 | 1.74 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.29 | 1.85 | 0.87 | 0.845 | 1.38 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 3.34 | 1.85 | 0.87 | 0.845 | 1.38 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 3.34 | 1.85 | 0.87 | 0.845 | 1.38 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.221 | 0.267 | 0.163 | 0.17 | 0.297 |
Dividends per Share | |||||
Special Dividends per Share |